載入...
Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial
AIMS: To assess the dose‐related effects of sotagliflozin, a novel dual inhibitor of sodium‐glucose co‐transporters‐1 and ‐2, in type 1 diabetes (T1D). MATERIALS AND METHODS: In this 12‐week, multicentre, randomized, double‐blind, placebo‐controlled dose‐ranging trial, adults with T1D were randomize...
Na minha lista:
| 發表在: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Blackwell Publishing Ltd
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6851757/ https://ncbi.nlm.nih.gov/pubmed/31264767 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13825 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|